Use of cross-linked hemoglobin in treating subarachnoid hemorrha

Details Use of cross-linked hemoglobin in treating subarachnoid hemorrha Use of cross-linked hemoglobin in treating subarachnoid hemorrha

1996-11-12

1998-12-29

Henlev, III, Raymond

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

A61K 3816

Patent

active

058542108

ABSTRACT:
A hemoglobin preparation is administered following subarachnoid hemorrhage to dramatically reduce the tissue area of hypoperfusion and the extent of neuronal damage in the area of hypoperfusion.

REFERENCES:
patent: Re34271 (1993-06-01), Walder
patent: 2464284 (1949-10-01), Alles
patent: 3238101 (1966-03-01), Fruhstorfer
patent: 3681459 (1972-08-01), Hughes et al.
patent: 3925344 (1975-12-01), Mazor
patent: 4001401 (1977-01-01), Bonsen et al.
patent: 4053590 (1977-10-01), Bonsen et al.
patent: 4103687 (1978-08-01), Ishii
patent: 4529719 (1985-07-01), Tye
patent: 4598064 (1986-07-01), Walder
patent: 4600531 (1986-07-01), Walder
patent: 4757052 (1988-07-01), Markov
patent: 4826811 (1989-05-01), Sehgal et al.
patent: 4988515 (1991-01-01), Buckberg
patent: 4994444 (1991-02-01), Zikria
patent: 5049695 (1991-09-01), Abraham et al.
patent: 5059712 (1991-10-01), Griffith
patent: 5079337 (1992-01-01), Leonard et al.
patent: 5110909 (1992-05-01), Dellacherie et al.
patent: 5122539 (1992-06-01), Abraham et al.
patent: 5128452 (1992-07-01), Hai et al.
patent: 5194590 (1993-03-01), Sehgal et al.
patent: 5248766 (1993-09-01), Nelson et al.
patent: 5248785 (1993-09-01), Abraham et al.
patent: 5268500 (1993-12-01), Lalezari et al.
patent: 5290803 (1994-03-01), Abraham et al.
patent: 5295944 (1994-03-01), Teicher et al.
patent: 5334706 (1994-08-01), Wong
patent: 5370870 (1994-12-01), Abraham et al.
patent: 5382680 (1995-01-01), Nho et al.
patent: 5386014 (1995-01-01), Nho et al.
patent: 5428007 (1995-06-01), Fischer et al.
patent: 5432191 (1995-07-01), Abraham et al.
patent: 5434168 (1995-07-01), Stokbroekx et al.
patent: 5439882 (1995-08-01), Feola et al.
patent: 5449759 (1995-09-01), Hoffman et al.
patent: 5464814 (1995-11-01), Sehgal et al.
patent: 5478806 (1995-12-01), Nho
patent: 5498421 (1996-03-01), Grinstaff et al.
patent: 5510464 (1996-04-01), Przybelski
patent: 5591710 (1997-01-01), Hsia
The Blood Sustitutes: Markets, Products and Red Cell Sourcing. The Marketing Research Bureau, Inc., pp. 182-186, 1994.
Asano et al., Endothelin: A Potential Modulator of Cerebral Vasospasm. European Journal of Pharmacology, vol. 190, pp. 365-372, 1990.
Asano et al., Endothelin and the Production of Cerebral Vasospasm in Dogs. Biochemical and Biophysical Research Communications, vol. 159, No. 3, pp. 1345-1351, 1989.
Barve et al., Dose-Dependent Effect of Diaspirin Crosslinked Hemoglobin on the Systemic and Regional Blood Circulation in Rats. Art. Cells, Blood Subs., and Immob. Biotech., vol. 24, No. 4, p. 306, 1996 (abstract).
Bilello et al., Diaspirin Cross Linked Hemoglobin (DCLHb): Control of Pressor Effect with Anti-Hypertensive Agents. ISBS 1993 Program and Abstracts, (1 page).
Bilello et al., Diaspirin Crosslinked Hemoglobin (DCLHb): Control of Pressor Effect with Anti-Hypertensive Agents. Art. Cells, Blood Subs., and Immob. Biotech., vol. 22, No. 3, pp. 819-825, 1994.
Biro et al. The Effect of Hemodilution with Stroma-Free Hemoglobin and Dextran on Collateral Perfusion of Ischemic Myocardium in the Dog. American Heart Journal, vol. 99, No. 1, pp. 64-75, 1980.
Bowes et al. Diaspirin Cross-Linked Hemogolbin Improves Neurological Outcome Following Reversible but Not Irreversible CNS Ischemia in Rabbits. Chemical Abstracts, vol. 122, No. 13, Abstract No. 151066q, pp. 45-46, 1995.
Bowes et al. Diaspirin Cross-linked Hemoglobin Improves Neurological Outcome Following Reversible But Not Irreversible CNS Ischemia in Rabbits. Department of Medicinal Chemistry, Virginia Commonwealth University, pp. 2253-2257, 1994.
Bowes et al. Hemodilution with Diaspirin Cross-Linked Hemoglobin (DCLHb) Reduces Neurological Damage Following Reversible But Not Irreversible CNS Ischemia in Rabbits. Soc. Neurosci., vol. 19, Abstract No. 673.8, p. 1643, 1993.
Bowman et al. Actions on the Cardiovascular System of an Inhibitory Material Extracted From the Bovine Retractor Penis. Br. J. Pharmac., vol. 72, pp. 365-372, 1981.
Buga et al. Endothelium-Derived Nitric Oxide Relaxes Nonvascular Smooth Muscle. European Journal of Pharmacology, vol. 161, pp. 61-71, 1989.
Burhop et al. Diaspirin Crosslinked Hemoglobin (DCLHb): Application in the Treatment of Hypovolemic Hemorrhagic Shock. Intl. J. Crit. Care Med., vol. 5, No. 2 Supplement, Abstract No. 19, 1994.
Byrne et al. Investigation of the Vasoconstrictor Action of Subarachnoid Haemoglobin in the Pig Cerebral Circulation in Vivo. Br. J. Pharmacol., vol. 97, pp. 669-674, 1989.
Chappell et al. Hemodilution with Diaspirin Cross-linked Hemoglobin Lowers Intracranial Pressure, Improves Cerebral Perfusion Pressure and Reduces Fluid Requirement Following Head Injury and Shock. Surgical Forum, vol. 46, No. 0, pp. 469-471, 1995.
Cheung et al. Preliminary Characterization of Vasocontractile Activities in Erythrocytes. Journal of Neurosurgery, vol. 53, pp. 37-43, 1980.
Chyatte et al. Cerebral Vasospasm: Evidence Supporting an Inflammatory Etiology. Cerebral Vasospasm, pp. 357-365, 1988.
Clower et al. Endothelial Injury following Experimental Subarachnoid Hemorrhage in Rats: Effects on Brain Blood Flow. The Anatomical Record, vol. 240, pp. 104-114, 1994.
Cocks et al. Oxyhaemoglobin Increases the Production of Endothelin-1 by Endothelial Cells in Culture. European Journal of Pharmacology, vol. 196, pp. 177-182, 1991.
Coetzee et al. Halothane and the Reperfusion Injury in the Intact Animal Model. Anesth. Analg., vol. 76, No. 4, pp. 734-744, 1993.
Cole et al. Hypervolemic-Hemodilution and Hypertension During Temporary Middle Cerebral Artery Occlusion in Rats: The Effect on Blood-Brain Barrier Permeability. The Canadian Journal of Neurological Sciences, vol. 17, No. 4, pp. 372-377, 1990.
Cole et al. Effects of Viscosity and Oxygen Content on Cerebral Blood Flow in Ischemic and Normal Rat Brain. Journal of the Neurological Sciences, vol. 124, pp. 15-20, 1994.
Cole et al. Focal Cerebral Ischemia in Rats: Effect of Oncotic Pressure of a Molecular Hemoglobin Preparation on Infarct Volume in Rats. Anesth. Analog, vol. 80, No. S82, 1995
Cole et al. Effects of Oncotic Pressure of a Molecular Hemoglobin Solution on Focal Cerebral Ischemia in Rats. Anesthesia and Analgesia, vol. 83, No. 2, pp. 342-347, 1992.
Cole et al. Hemodilution and Hypertension Effects on Cerebral Hemorrhage in Cerebral Ischemia in Rats. Stroke, vol. 21, No. 9, pp. 1333-1339, 1990.
Cole et al. The Effect of Molecular Hemoglobin's Nitric Oxide Binding Properties on Cerebral Ischemic Injury in Rats. Anesth. Analog, vol. 80, No. S83, 1995.
Cole et al. Diaspirin Crosslinked Hemoglobin (DCLHb): Effect of Hemodilution During Focal Cerebral Ischemia In Rats. ISBS 1993 Program and Abstracts, (1 page).
Cole et al. Diaspirin Crosslinked Hemoglobin (DCLHb): Effect of Hemodilution During Focal Cerebral Ischemia in Rats. Art. Cells, Blood Subs., and Immob. Biotech., vol. 22, No. 3, pp. 813-818, 1994.
Cole et al. Hemodilution During Cerebral Ischemia in Rats: Effects of Stroma-Free Hemoglobin on Brain Injury. Anesth. Analog, vol. 74, Abstract S50, 1992.
Cole et al. Focal Cerebral Ischemia in Rats: Effect of Hypervolemic Hemodilution with Diaspirin Cross-Linked Hemoglobin Versus Albumin on Brain Injury and Edema. Anesthesiology, vol. 78, No. 2, pp. 335-342, 1993.
Cole et al. Focal Cerebral Ischemia in Rats: Effect of Hemodilution with x--x Cross-Linked Hemoglobin on Brain Injury and Edema. The Canadian Journal of Neurological Sciences, vol. 20, No. 1, pp. 30-36, 1993.
Cole et al. Focal Cerebral Ischemia in Rats: Effect of Hemodilution with x--x Cross-Linked Hemoglobin on CBF. Journal of Cerebral Blood Flow & Metabolism, vol. 12, No. 6, pp. 971-976, 1992.
Cole et al. Control of Cross-linked Hemoglobin's (Hb) Pressor Response. Circ. Shock, vol. 80, No. 10, p. 221a, 1992 (abstract).
Cosentino et al. Does Endothelin-1 Play a Role in the Pathogenesis of Cerebral Vasospasm? Stroke, vol. 25, No. 4, pp. 904-908, 1994.
Deby-Dupont et al. Hemoglobin-based Red Cell Substitutes: Preliminary Human Studies. Yearbook of Intensive Care and Emerg. Med., pp. 264-275, 1994.
Delgado et al. Subarachnoid Haemorrhage in the Rat: Angiography and Flourescence Microscopy of

Affiliated with

Also associated with

Rating

Use of cross-linked hemoglobin in treating subarachnoid hemorrha does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of cross-linked hemoglobin in treating subarachnoid hemorrha, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of cross-linked hemoglobin in treating subarachnoid hemorrha will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1424858